Certificate of Analysis
Purity
≥98.0%
Method
HPLC / MS
Testing
Third-Party
COA Status
Available
PT-141
A melanocortin research peptide studied in laboratory models involving melanocortin receptor binding analysis and neuropeptide pathway characterization.
Choose Pack Size
Quantity
Research Use Only — All products are intended strictly for laboratory research purposes and are not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
About PT-141
PT-141 (Bremelanotide) is a cyclic synthetic heptapeptide melanocortin receptor agonist derived from the MT-II (Melanotan II) scaffold. The molecule features a norleucine (Nle) substitution at position 4, a D-Phe residue at position 7 for enhanced receptor affinity and selectivity, and a lactam bridge between aspartic acid and lysine that constrains the backbone into a β-turn conformation essential for receptor engagement. PT-141 exhibits agonist activity at melanocortin receptor subtypes MC1R, MC3R, MC4R, and MC5R in binding assay systems.
Research investigations of PT-141 have characterized its binding affinity profile across melanocortin receptor subtypes, downstream cAMP signaling activation in heterologous expression systems, receptor selectivity relative to α-MSH and linear peptide analogs, and structure-activity relationships of the cyclic melanocortin pharmacophore. Scientific interest in MC4R-selective agonism has made this compound a frequently used tool in central melanocortin circuit research in preclinical models. This compound is provided for qualified laboratory research purposes only.
Peptide / Compound Information
| Property | Value |
|---|---|
| Peptide Sequence | Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH (cyclic via lactam) |
| Molecular Formula | C50H68N14O10 |
| Molecular Weight | 1,025.2 g/mol |
| CAS Number | 189691-06-3 |
| PubChem CID | 9941249 |
| Synonyms | Bremelanotide, PT-141, Vyleesi (research ref.) |
Source: PubChem — for research reference only.
Lyophilized Research Peptides
This product is supplied in lyophilized (freeze-dried) form — a process that extends shelf life and preserves peptide purity and structural integrity during storage. No fillers, excipients, or preservatives are used in the lyophilization process. The lyophilized powder should be reconstituted with an appropriate research-grade solvent in a controlled laboratory environment prior to use in in vitro or preclinical assay systems.
99%+
PURITY
Third Party Tested
Independently verified by ISO-accredited laboratories. Batch-specific COAs available on request.
GMP
CERT.
GMP Manufacturing Standards
Synthesized in registered facilities following Good Manufacturing Practices with full chain-of-custody documentation.
FAST
SHIP
Best in Class Fulfillment
Same-day fulfillment on qualifying orders. Secure cold-chain packaging. Domestic and international research shipping.
ZERO
FILLERS
Zero Fillers or Additives
Pure active compounds only. Lyophilized without fillers or preservatives. Composition independently verified.
Scientific Content Review
All technical product descriptions, molecular data, and research context on this page have been prepared with reference to published scientific literature and PubChem compound databases. Content is intended for informational purposes in a research catalog context and does not constitute medical advice or claim therapeutic efficacy.
PT-141 is a research compound available for controlled laboratory investigation and scientific study. This product is intended strictly for in vitro research, preclinical investigation, and analytical characterization by qualified researchers. Not for human consumption.
Category
Other
Purity
≥98.0%
Available Sizes
10MG
COA
Available